Abstract
Src family tyrosine kinase (SFK) activation is closely associated with the progression of ovarian cancer, making SFKs a primary target for therapeutic intervention. This study investigated the antitumor activity of dasatinib, a tyrosine kinase inhibitor, both as a monotherapy and in combination with paclitaxel. High levels of phosphorylated Src (p-Src) were observed across six ovarian cancer cell lines, indicating active Src signaling. Crucially, paclitaxel treatment was found to further increase p-Src expression, suggesting a potential survival mechanism triggered by chemotherapy. Dasatinib treatment effectively downregulated p-Src and induced apoptosis. When combined, dasatinib and paclitaxel demonstrated significant synergy in vitro and potent tumor growth inhibition in vivo, with inhibitory rates reaching up to 76.7% in murine xenograft models.
Introduction
Ovarian cancer remains a significant clinical challenge, primarily due to high relapse rates and the development of resistance to standard platinum- and taxane-based chemotherapies. Approximately 75% of patients eventually face chemoresistance, necessitating the search for targeted therapies that can enhance the efficacy of traditional treatments. Src family kinases (SFKs) are known to drive tumor progression, survival, and metastasis. While dasatinib is FDA-approved for certain leukemias, its potential to sensitize ovarian cancer to paclitaxel required further investigation. This study explores whether dasatinib can overcome resistance by targeting the Src signaling pathway.
Materials and Methods
The researchers utilized six human ovarian cancer cell lines: A2780, HO8910, OVCAR3, CAOV3, COC1, and SKOV3.
- Molecular Analysis: Western blotting was employed to measure the expression of Src and its active form, p-Src-Y416.
- Cellular Assays: MTT assays were used to evaluate cell viability, while Annexin V-fluorescein isothiocyanate staining measured apoptosis rates.
- Synergy Quantification: The Combination Index (CI) was calculated using Calcusyn software to determine if drug interactions were synergistic (CI < 1).
- In Vivo Modeling: BALB/c nude mice were used to establish xenografts of A2780 and HO8910 cells to assess tumor volume and weight over a 31-day treatment period.
Results
The "Paclitaxel Paradox": Src Activation
A key finding of this study was that paclitaxel treatment, while intended to kill cancer cells, actually increased the levels of active p-Src. This "Paclitaxel Paradox" suggests that the chemotherapy itself may inadvertently trigger a survival pathway in the cancer cells, potentially contributing to drug resistance.
Dasatinib as a Potent Growth Inhibitor
Dasatinib monotherapy demonstrated clear anti-ovarian cancer properties. It inhibited cell growth in a dose-dependent manner across the tested lines, with IC50 values of 7.30 µM for A2780 and 2.51 µM for HO8910 cells.
Synergistic Effects and In Vivo Efficacy
When combined, dasatinib effectively neutralized the paclitaxel-induced Src activation. This combination led to significantly higher rates of apoptosis compared to either drug alone. For instance, in HO8910 cells, the combination treatment increased the apoptosis rate to 43.6%, compared to 22.0% for paclitaxel alone.
In mouse models, the synergy was even more pronounced. The combination therapy achieved a Tumor Growth Inhibitory (TIR) rate of 76.7% for A2780 tumors and 58.5% for HO8910 tumors. Importantly, the treatment was well-tolerated, with no significant weight loss or acute toxicity observed in the subjects.
Discussion and Conclusion
This study highlights the critical role of the Src signaling pathway in ovarian cancer's response to chemotherapy. By demonstrating that paclitaxel activates Src and that dasatinib can effectively block this activation, the researchers have identified a clear molecular mechanism for synergy. The combination of dasatinib and paclitaxel not only inhibits proliferation but also actively promotes programmed cell death more effectively than standard care. These findings suggest that Src inhibition could be a viable clinical strategy to enhance the efficacy of paclitaxel and overcome chemoresistance in ovarian cancer patients.
Summary updated